Cleerly LABS vs Viz HCM

Viz HCM excels in usability by offering real-time ECG analysis and mobile-based alerts, enabling immediate notification and coordination for multidisciplinary care teams. This seamless integration into existing clinical workflows and mobile accessibility provides a broader and more immediate impact on daily tasks compared to Cleerly LABS' web-based platform, which focuses on detailed CCTA analysis for radiologists and cardiologists.

While Cleerly LABS provides novel, quantitative insights into coronary plaque and ischemia for personalized CAD management, Viz HCM addresses a critical unmet need by rapidly identifying suspected Hypertrophic Cardiomyopathy (HCM) from routine ECGs. This significantly reduces diagnosis time for a condition often missed, leading to earlier intervention and improved patient outcomes for a serious, often undiagnosed disease.

Both tools have achieved significant reimbursement milestones. However, Cleerly LABS has secured broader coverage from major commercial payers (UnitedHealthcare, Cigna, Aetna) and Medicare, with a Category I CPT code effective January 1, 2026, and a global reimbursement rate of $1,026 per analysis. This indicates a stronger financial value proposition and wider patient access through established billing pathways compared to Viz HCM's CMS reimbursement for AI-powered ECG analysis at $128.90.

Both tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, BAA, and robust integration capabilities. However, Viz HCM has a more established and broader presence, deployed in over 2,000 hospitals and supporting multiple FDA-cleared AI algorithms on its platform. This indicates a more mature and widely adopted enterprise solution for various conditions.

While Cleerly LABS is innovative in pioneering detailed, quantitative plaque characterization from CCTA, Viz HCM achieved a De Novo FDA approval, establishing a new regulatory category for AI-driven cardiovascular notification software. Its real-time, system-wide ECG analysis for a subtle, often undiagnosed condition, coupled with intelligent care coordination, represents a significant innovation in accelerating diagnosis and improving patient pathways for HCM.

Viz HCM appears to offer more comprehensive and publicly documented support and documentation resources. Its website explicitly lists a 'Help Center,' 'Customer Resources,' 'User Guides,' 'Viz Academy,' and an 'HCM Education Series,' alongside extensive clinical research and publications. While Cleerly mentions implementation specialists and guidance, Viz HCM's breadth of listed resources suggests a more robust and accessible support ecosystem for its users.